Lucey Brendan P, Fagan Anne M, Holtzman David M, Morris John C, Bateman Randall J
Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8111, St Louis, MO, 63110, USA.
Mol Neurodegener. 2017 May 8;12(1):36. doi: 10.1186/s13024-017-0161-4.
To assess stages of Alzheimer's disease (AD) pathogenesis and the efficacy of drugs during clinical trials, there has been immense interest in the field to establish baseline cerebrospinal fluid (CSF) concentrations for potential AD biomarkers such as amyloid-β (Aβ) and tau. Significant within-person variations in CSF Aβ concentrations over time found that this variation followed the sleep-wake cycle. A recent paper in Molecular Neurodegeneration reported the absence of diurnal variations in multiple classical and candidate AD biomarkers, such as soluble APP, Aβ, tau, p-tau, YKL-40, VILIP-1, or apolipoprotein E. This commentary addresses these apparently discordant results regarding the diurnal variability of APP and Aβ compared with the literature. Despite our concerns, we appreciate the authors' interest in this important topic and contribution to improve our knowledge about the factors influencing Aβ diurnal variation.
为了在临床试验期间评估阿尔茨海默病（AD）发病机制的阶段以及药物疗效，该领域对建立潜在AD生物标志物（如淀粉样蛋白-β（Aβ）和tau）的脑脊液（CSF）基线浓度有着浓厚兴趣。随着时间的推移，脑脊液Aβ浓度存在显著的个体内差异，发现这种差异遵循睡眠-觉醒周期。《分子神经退行性变》最近发表的一篇论文报道，多种经典和候选AD生物标志物（如可溶性APP、Aβ、tau、p-tau、YKL-40、VILIP-1或载脂蛋白E）不存在昼夜变化。这篇评论讨论了与文献相比，关于APP和Aβ昼夜变异性这些明显不一致的结果。尽管我们有所担忧，但我们赞赏作者对这一重要主题的关注以及为增进我们对影响Aβ昼夜变化因素的了解所做出的贡献。
